Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

A bacterial secreted translocator hijacks riboregulators to control type III secretion in response to host cell contact.

Kusmierek M, Hoßmann J, Witte R, Opitz W, Vollmer I, Volk M, Heroven AK, Wolf-Watz H, Dersch P.

PLoS Pathog. 2019 Jun 7;15(6):e1007813. doi: 10.1371/journal.ppat.1007813. [Epub ahead of print]

2.

Characterization of the Ruler Protein Interaction Interface on the Substrate Specificity Switch Protein in the Yersinia Type III Secretion System.

Ho O, Rogne P, Edgren T, Wolf-Watz H, Login FH, Wolf-Watz M.

J Biol Chem. 2017 Feb 24;292(8):3299-3311. doi: 10.1074/jbc.M116.770255. Epub 2016 Dec 30.

3.

Increased plasmid copy number is essential for Yersinia T3SS function and virulence.

Wang H, Avican K, Fahlgren A, Erttmann SF, Nuss AM, Dersch P, Fallman M, Edgren T, Wolf-Watz H.

Science. 2016 Jul 29;353(6298):492-5. doi: 10.1126/science.aaf7501. Epub 2016 Jun 30.

4.

YscU/FlhB of Yersinia pseudotuberculosis Harbors a C-terminal Type III Secretion Signal.

Login FH, Wolf-Watz H.

J Biol Chem. 2015 Oct 23;290(43):26282-91. doi: 10.1074/jbc.M114.633677. Epub 2015 Sep 3.

5.

A 2-pyridone-amide inhibitor targets the glucose metabolism pathway of Chlamydia trachomatis.

Engström P, Krishnan KS, Ngyuen BD, Chorell E, Normark J, Silver J, Bastidas RJ, Welch MD, Hultgren SJ, Wolf-Watz H, Valdivia RH, Almqvist F, Bergström S.

MBio. 2014 Dec 30;6(1):e02304-14. doi: 10.1128/mBio.02304-14.

6.

Negatively charged lipid membranes promote a disorder-order transition in the Yersinia YscU protein.

Weise CF, Login FH, Ho O, Gröbner G, Wolf-Watz H, Wolf-Watz M.

Biophys J. 2014 Oct 21;107(8):1950-1961. doi: 10.1016/j.bpj.2014.09.005.

7.

Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.

Engström P, Nguyen BD, Normark J, Nilsson I, Bastidas RJ, Gylfe A, Elofsson M, Fields KA, Valdivia RH, Wolf-Watz H, Bergström S.

J Bacteriol. 2013 Sep;195(18):4221-30. doi: 10.1128/JB.00506-13. Epub 2013 Jul 12.

8.

Metabolic profiling for detection of Staphylococcus aureus infection and antibiotic resistance.

Antti H, Fahlgren A, Näsström E, Kouremenos K, Sundén-Cullberg J, Guo Y, Moritz T, Wolf-Watz H, Johansson A, Fallman M.

PLoS One. 2013;8(2):e56971. doi: 10.1371/journal.pone.0056971. Epub 2013 Feb 25.

9.

Type III secretion translocon assemblies that attenuate Yersinia virulence.

Costa TR, Amer AA, Farag SI, Wolf-Watz H, Fällman M, Fahlgren A, Edgren T, Francis MS.

Cell Microbiol. 2013 Jul;15(7):1088-110. doi: 10.1111/cmi.12100. Epub 2013 Jan 21.

PMID:
23279117
10.

Autoproteolysis and intramolecular dissociation of Yersinia YscU precedes secretion of its C-terminal polypeptide YscU(CC).

Frost S, Ho O, Login FH, Weise CF, Wolf-Watz H, Wolf-Watz M.

PLoS One. 2012;7(11):e49349. doi: 10.1371/journal.pone.0049349. Epub 2012 Nov 21.

11.

Small molecule screening for inhibitors of the YopH phosphatase of Yersinia pseudotuberculosis.

Eriksson J, Grundström C, Sauer-Eriksson AE, Sauer UH, Wolf-Watz H, Elofsson M.

Adv Exp Med Biol. 2012;954:357-63. doi: 10.1007/978-1-4614-3561-7_43. No abstract available.

PMID:
22782782
12.

Type III secretion in Yersinia: injectisome or not?

Edgren T, Forsberg A, Rosqvist R, Wolf-Watz H.

PLoS Pathog. 2012;8(5):e1002669. doi: 10.1371/journal.ppat.1002669. Epub 2012 May 10. No abstract available.

13.

Yersinia pseudotuberculosis effector YopJ subverts the Nod2/RICK/TAK1 pathway and activates caspase-1 to induce intestinal barrier dysfunction.

Meinzer U, Barreau F, Esmiol-Welterlin S, Jung C, Villard C, Léger T, Ben-Mkaddem S, Berrebi D, Dussaillant M, Alnabhani Z, Roy M, Bonacorsi S, Wolf-Watz H, Perroy J, Ollendorff V, Hugot JP.

Cell Host Microbe. 2012 Apr 19;11(4):337-51. doi: 10.1016/j.chom.2012.02.009.

14.

Concerted actions of a thermo-labile regulator and a unique intergenic RNA thermosensor control Yersinia virulence.

Böhme K, Steinmann R, Kortmann J, Seekircher S, Heroven AK, Berger E, Pisano F, Thiermann T, Wolf-Watz H, Narberhaus F, Dersch P.

PLoS Pathog. 2012 Feb;8(2):e1002518. doi: 10.1371/journal.ppat.1002518. Epub 2012 Feb 16.

15.

Optimization of a sample preparation method for the metabolomic analysis of clinically relevant bacteria.

Marcinowska R, Trygg J, Wolf-Watz H, Mortiz T, Surowiec I.

J Microbiol Methods. 2011 Oct;87(1):24-31. doi: 10.1016/j.mimet.2011.07.001. Epub 2011 Jul 13.

PMID:
21763728
16.

The RACK1 signaling scaffold protein selectively interacts with Yersinia pseudotuberculosis virulence function.

Thorslund SE, Edgren T, Pettersson J, Nordfelth R, Sellin ME, Ivanova E, Francis MS, Isaksson EL, Wolf-Watz H, Fällman M.

PLoS One. 2011 Feb 10;6(2):e16784. doi: 10.1371/journal.pone.0016784.

17.

Translocation of surface-localized effectors in type III secretion.

Akopyan K, Edgren T, Wang-Edgren H, Rosqvist R, Fahlgren A, Wolf-Watz H, Fallman M.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1639-44. doi: 10.1073/pnas.1013888108. Epub 2011 Jan 10.

18.

Alternative endogenous protein processing via an autophagy-dependent pathway compensates for Yersinia-mediated inhibition of endosomal major histocompatibility complex class II antigen presentation.

Rüssmann H, Panthel K, Köhn B, Jellbauer S, Winter SE, Garbom S, Wolf-Watz H, Hoffmann S, Grauling-Halama S, Geginat G.

Infect Immun. 2010 Dec;78(12):5138-50. doi: 10.1128/IAI.00155-10. Epub 2010 Sep 27.

19.

[Virulence blocking antibiotics. Anti-bacterial agents with completely new action mechanisms].

Sundin C, Elofsson M, Wolf-Watz H, Rosell S.

Lakartidningen. 2009 Sep 30-Oct 6;106(40):2543-5. Review. Swedish. No abstract available.

PMID:
19908625
20.

The membrane localization domain is required for intracellular localization and autoregulation of YopE in Yersinia pseudotuberculosis.

Isaksson EL, Aili M, Fahlgren A, Carlsson SE, Rosqvist R, Wolf-Watz H.

Infect Immun. 2009 Nov;77(11):4740-9. doi: 10.1128/IAI.00333-09. Epub 2009 Aug 17.

21.

Autoproteolysis of YscU of Yersinia pseudotuberculosis is important for regulation of expression and secretion of Yop proteins.

Björnfot AC, Lavander M, Forsberg A, Wolf-Watz H.

J Bacteriol. 2009 Jul;191(13):4259-67. doi: 10.1128/JB.01730-08. Epub 2009 Apr 24.

22.

Attenuation and preserved immunogenic potential of Yersinia pseudotuberculosis mutant strains evidenced in oral pig model.

Najdenski H, Golkocheva-Markova E, Kussovski V, Vesselinova A, Garbom S, Wolf-Watz H.

Zoonoses Public Health. 2009 May;56(4):157-68. doi: 10.1111/j.1863-2378.2008.01153.x. Epub 2008 Sep 11.

PMID:
18793276
23.

Nod2 mediates susceptibility to Yersinia pseudotuberculosis in mice.

Meinzer U, Esmiol-Welterlin S, Barreau F, Berrebi D, Dussaillant M, Bonacorsi S, Chareyre F, Niwa-Kawakita M, Alberti C, Sterkers G, Villard C, Lesuffleur T, Peuchmaur M, Karin M, Eckmann L, Giovannini M, Ollendorff V, Wolf-Watz H, Hugot JP.

PLoS One. 2008 Jul 23;3(7):e2769. doi: 10.1371/journal.pone.0002769.

24.

The influence of in vitro fitness defects on pneumococcal ability to colonize and to cause invasive disease.

Fernebro J, Blomberg C, Morfeldt E, Wolf-Watz H, Normark S, Normark BH.

BMC Microbiol. 2008 Apr 18;8:65. doi: 10.1186/1471-2180-8-65.

25.

Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.

Keyser P, Elofsson M, Rosell S, Wolf-Watz H.

J Intern Med. 2008 Jul;264(1):17-29. doi: 10.1111/j.1365-2796.2008.01941.x. Epub 2008 Apr 3.

26.

Regulation of Yersinia Yop-effector delivery by translocated YopE.

Aili M, Isaksson EL, Carlsson SE, Wolf-Watz H, Rosqvist R, Francis MS.

Int J Med Microbiol. 2008 Apr;298(3-4):183-92. Epub 2007 Jun 26.

PMID:
17597003
27.

Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium.

Negrea A, Bjur E, Ygberg SE, Elofsson M, Wolf-Watz H, Rhen M.

Antimicrob Agents Chemother. 2007 Aug;51(8):2867-76. Epub 2007 Jun 4.

28.

Identification of a molecular target for the Yersinia protein kinase A.

Navarro L, Koller A, Nordfelth R, Wolf-Watz H, Taylor S, Dixon JE.

Mol Cell. 2007 May 25;26(4):465-77.

29.

Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors.

Hudson DL, Layton AN, Field TR, Bowen AJ, Wolf-Watz H, Elofsson M, Stevens MP, Galyov EE.

Antimicrob Agents Chemother. 2007 Jul;51(7):2631-5. Epub 2007 May 14.

30.

Phenotypic characterization of a virulence-associated protein, VagH, of Yersinia pseudotuberculosis reveals a tight link between VagH and the type III secretion system.

Garbom S, Olofsson M, Björnfot AC, Srivastava MK, Robinson VL, Oyston PC, Titball RW, Wolf-Watz H.

Microbiology. 2007 May;153(Pt 5):1464-73.

PMID:
17464060
31.

Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.

Bailey L, Gylfe A, Sundin C, Muschiol S, Elofsson M, Nordström P, Henriques-Normark B, Lugert R, Waldenström A, Wolf-Watz H, Bergström S.

FEBS Lett. 2007 Feb 20;581(4):587-95. Epub 2007 Jan 17.

32.

Protein delivery into eukaryotic cells by type III secretion machines.

Galán JE, Wolf-Watz H.

Nature. 2006 Nov 30;444(7119):567-73. Review.

PMID:
17136086
33.

A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis.

Muschiol S, Bailey L, Gylfe A, Sundin C, Hultenby K, Bergström S, Elofsson M, Wolf-Watz H, Normark S, Henriques-Normark B.

Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14566-71. Epub 2006 Sep 14.

34.

Functional analysis of the YopE GTPase-activating protein (GAP) activity of Yersinia pseudotuberculosis.

Aili M, Isaksson EL, Hallberg B, Wolf-Watz H, Rosqvist R.

Cell Microbiol. 2006 Jun;8(6):1020-33.

PMID:
16681842
35.

The Ser/Thr kinase activity of the Yersinia protein kinase A (YpkA) is necessary for full virulence in the mouse, mollifying phagocytes, and disrupting the eukaryotic cytoskeleton.

Wiley DJ, Nordfeldth R, Rosenzweig J, DaFonseca CJ, Gustin R, Wolf-Watz H, Schesser K.

Microb Pathog. 2006 May;40(5):234-43. Epub 2006 Apr 19.

PMID:
16626927
36.

Induction of CD8+ T cell responses by Yersinia vaccine carrier strains.

Wiedig CA, Kramer U, Garbom S, Wolf-Watz H, Autenrieth IB.

Vaccine. 2005 Oct 10;23(42):4984-98.

PMID:
15985316
37.

Small-molecule inhibitors specifically targeting type III secretion.

Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M.

Infect Immun. 2005 May;73(5):3104-14.

38.

The YopD translocator of Yersinia pseudotuberculosis is a multifunctional protein comprised of discrete domains.

Olsson J, Edqvist PJ, Bröms JE, Forsberg A, Wolf-Watz H, Francis MS.

J Bacteriol. 2004 Jul;186(13):4110-23.

39.

Visualisation of zebrafish infection by GFP-labelled Vibrio anguillarum.

O'Toole R, Von Hofsten J, Rosqvist R, Olsson PE, Wolf-Watz H.

Microb Pathog. 2004 Jul;37(1):41-6.

PMID:
15194159
40.

Identification of novel virulence-associated genes via genome analysis of hypothetical genes.

Garbom S, Forsberg A, Wolf-Watz H, Kihlberg BM.

Infect Immun. 2004 Mar;72(3):1333-40.

41.

Experimental infections with wild and mutant Yersinia pseudotuberculosis strains in rabbits.

Najdenski H, Vesselinova A, Golkocheva E, Garbom S, Wolf-Watz H.

J Vet Med B Infect Dis Vet Public Health. 2003 Aug;50(6):280-8.

PMID:
14628999
42.

In vitro GAP activity towards RhoA, Rac1 and Cdc42 is not a prerequisite for YopE induced HeLa cell cytotoxicity.

Aili M, Telepnev M, Hallberg B, Wolf-Watz H, Rosqvist R.

Microb Pathog. 2003 Jun;34(6):297-308.

PMID:
12782482
43.

Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigen-specific CD4 and CD8 T-cell induction.

Rüssmann H, Gerdemann U, Igwe EI, Panthel K, Heesemann J, Garbom S, Wolf-Watz H, Geginat G.

Infect Immun. 2003 Jun;71(6):3463-72.

44.

Characterization of infections with wild and mutant Yersinia pseudotuberculosis strains in rabbit oral model.

Najdenski H, Vesselinova A, Golkocheva E, Garbom S, Wolf-Watz H.

Adv Exp Med Biol. 2003;529:117-20. No abstract available.

PMID:
12756740
45.

Characterisation of the type III secretion protein YscU in Yersinia pseudotuberculosis. YscU cleavage--dispensable for TTSS but essential for survival.

Lavander M, Sundberg L, Edqvist PJ, Lloyd SA, Wolf-Watz H, Forsberg A.

Adv Exp Med Biol. 2003;529:109-12. No abstract available.

PMID:
12756738
46.

Salicylanilides are potent inhibitors of type III secretion in Yersinia.

Kauppi AM, Nordfelth R, Hägglund U, Wolf-Watz H, Elofsson M.

Adv Exp Med Biol. 2003;529:97-100. No abstract available.

PMID:
12756735
47.

Targeting bacterial virulence: inhibitors of type III secretion in Yersinia.

Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M.

Chem Biol. 2003 Mar;10(3):241-9.

PMID:
12670538
48.

YscP and YscU regulate substrate specificity of the Yersinia type III secretion system.

Edqvist PJ, Olsson J, Lavander M, Sundberg L, Forsberg A, Wolf-Watz H, Lloyd SA.

J Bacteriol. 2003 Apr;185(7):2259-66.

49.

Interaction between the Yersinia protein tyrosine phosphatase YopH and eukaryotic Cas/Fyb is an important virulence mechanism.

Deleuil F, Mogemark L, Francis MS, Wolf-Watz H, Fällman M.

Cell Microbiol. 2003 Jan;5(1):53-64.

PMID:
12542470
50.

GAP activity of Yersinia YopE.

Aili M, Hallberg B, Wolf-Watz H, Rosqvist R.

Methods Enzymol. 2002;358:359-70. No abstract available.

PMID:
12474400

Supplemental Content

Loading ...
Support Center